Mannosylated and lipid A-incorporating cationic liposomes constituting microneedle arrays as an effective oral mucosal HBV vaccine applicable in the controlled temperature chain

Colloids and Surfaces B: Biointerfaces

Volumn 126, Issue , 2015, Pages 520-530

  Wang, Ting ^a   Zhen, Yuanyuan ^a   Ma, Xiaoyu ^a   Wei, Biao ^a   Li, Shuqin ^a   Wang, Ning ^b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b HEFEI UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

C type lectin receptor; Freeze drying; Liposomes; Microneedles; Mucosal immunization

Indexed keywords

CHAINS; EMULSIFICATION; IMMUNIZATION; LIPOSOMES; MAMMALS; T-CELLS; VACCINES; VIRUSES;

ASSOCIATION EFFICIENCY; C-TYPE LECTINS; CATIONIC LIPOSOMES; CONTROLLED TEMPERATURE; FREEZE DRYING; MICRONEEDLE ARRAYS; MICRONEEDLES; MUCOSAL IMMUNIZATION;

NEEDLES;

CATIONIC LIPOSOME; CHOLESTEROL; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; LIPID A; LIPOSOME; MACROGOL; MANNOSE; UNCLASSIFIED DRUG; CATION;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG STORAGE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HOST RESISTANCE; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; LIPOSOMAL DELIVERY; MICRONEEDLE; MUCOSAL IMMUNITY; NONHUMAN; SALIVA LEVEL; SPLEEN CELL; STORAGE TEMPERATURE; SWINE; TH1 CELL; TH2 CELL; THERMOSTABILITY; VACCINATION; ANIMAL; CHEMISTRY; DEVICES; HELPER CELL; IMMUNOLOGY; INBRED MOUSE STRAIN; MICROINJECTION; MOUSE; MOUTH MUCOSA; TEMPERATURE;

HEPATITIS B VIRUS; MUS; SUS;

ANIMALS; CATIONS; FEMALE; HEPATITIS B VACCINES; IMMUNITY, MUCOSAL; LIPID A; LIPOSOMES; MANNOSE; MICE; MICE, INBRED STRAINS; MICROINJECTIONS; MOUTH MUCOSA; T-LYMPHOCYTES, HELPER-INDUCER; TEMPERATURE;

EID: 84923027949     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2015.01.005     Document Type: Article

References (41)

1. WHO WHO Fact Sheets: Hepatitis B (Visited in June 2014), Hepatitis B 2014, WHO.
2. Michel M.L., Tiollais P. Hepatitis B vaccines: protective efficacy and therapeutic potential. Pathol. Biol. (Paris) 2010, 58:288-295.
3. Plotkin S.A. Vaccines: past, present and future. Nat. Med. 2005, 11:S5-S11.
4. Saade F., Honda-Okubo Y., Trec S., Petrovsky N. A novel hepatitis B vaccine containing Advax, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. Vaccine 2013, 31:1999-2007.
5. Schiott A., Larsson K., Manniche S., Kalliomaki S., Heydenreich A.V., Dalsgaard K., Kirkby N. Posintro-HBsAg, a modified ISCOM including HBsAg, induces strong cellular and humoral responses. Int. J. Pharm. 2011, 414:312-320.
6. Buchmann P., Dembek C., Kuklick L., Jager C., Tedjokusumo R., von Freyend M.J., Drebber U., Janowicz Z., Melber K., Protzer U. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine 2013, 31:1197-1203.
7. Vandepapeliere P., Horsmans Y., Moris P., Van Mechelen M., Janssens M., Koutsoukos M., Van Belle P., Clement F., Hanon E., Wettendorff M., Garcon N., Leroux-Roels G. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 2008, 26:1375-1386.
8. Kutscher S., Bauer T., Dembek C., Sprinzl M., Protzer U. Design of therapeutic vaccines: hepatitis B as an example. Microb. Biotechnol. 2012, 5:270-282.
9. Makidon P.E., Bielinska A.U., Nigavekar S.S., Janczak K.W., Knowlton J., Scott A.J., Mank N., Cao Z., Rathinavelu S., Beer M.R., Wilkinson J.E., Blanco L.P., Landers J.J., Baker J.R. Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS ONE 2008, 3:e2954.
10. Subbiah R., Ramalingam P., Ramasundaram S., Kim do Y., Park K., Ramasamy M.K., Choi K.J. N,N,N-trimethyl chitosan nanoparticles for controlled intranasal delivery of HBV surface antigen. Carbohydr. Polym. 2012, 89:1289-1297.
11. Mishra N., Tiwari S., Vaidya B., Agrawal G.P., Vyas S.P. Lectin anchored PLGA nanoparticles for oral mucosal immunization against hepatitis B. J. Drug Target. 2011, 19:67-78.
12. Prausnitz M.R., Mikszta J.A., Cormier M., Andrianov A.K. Microneedle-based vaccines. Curr. Top. Microbiol. Immunol. 2009, 333:369-393.
13. del Pilar Martin M., Weldon W.C., Zarnitsyn V.G., Koutsonanos D.G., Akbari H., Skountzou I., Jacob J., Prausnitz M.R., Compans R.W. Local response to microneedle-based influenza immunization in the skin. MBio 2012, 3. e00012-00012.
14. van der Maaden K., Jiskoot W., Bouwstra J. Microneedle technologies for (trans)dermal drug and vaccine delivery. J. Control. Release 2012, 161:645-655.
15. Choi S.O., Kim Y.C., Lee J.W., Park J.H., Prausnitz M.R., Allen M.G. Intracellular protein delivery and gene transfection by electroporation using a microneedle electrode array. Small 2012, 8:1081-1091.
16. Cutler C.W., Jotwani R. Dendritic cells at the oral mucosal interface. J. Dent. Res. 2006, 85:678-689.
17. Casella C.R., Mitchell T.C. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell. Mol. Life Sci. 2008, 65:3231-3240.
18. Irache J.M., Salman H.H., Gamazo C., Espuelas S. Mannose-targeted systems for the delivery of therapeutics. Expert Opin. Drug Deliv. 2008, 5:703-724.
19. Wang N., Wang T., Zhang M., Chen R., Niu R., Deng Y. Mannose derivative and lipid A dually decorated cationic liposomes as an effective cold chain free oral mucosal vaccine adjuvant-delivery system. Eur. J. Pharm. Biopharm. 2014.
20. Morales J.O., McConville J.T. Novel strategies for the buccal delivery of macromolecules. Drug Dev. Ind. Pharm. 2014, 40:579-590.
21. Kweon M.N. Sublingual mucosa: a new vaccination route for systemic and mucosal immunity. Cytokine 2011, 54:1-5.
22. Zipursky S., Djingarey M.H., Lodjo J.C., Olodo L., Tiendrebeogo S., Ronveaux O. Benefits of using vaccines out of the cold chain: delivering meningitis A vaccine in a controlled temperature chain during the mass immunization campaign in Benin. Vaccine 2014, 32:1431-1435.
23. Guo L., Chen J., Qiu Y., Zhang S., Xu B., Gao Y. Enhanced transcutaneous immunization via dissolving microneedle array loaded with liposome encapsulated antigen and adjuvant. Int. J. Pharm. 2013, 447:22-30.
24. Wang T., Deng Y., Geng Y., Gao Z., Zou J., Wang Z. Preparation of submicron unilamellar liposomes by freeze-drying double emulsions. Biochim. Biophys. Acta 2006, 1758:222-231.
25. Wang T., Wang N., Jin X., Zhang K., Li T. A novel procedure for preparation of submicron liposomes-lyophilization of oil-in-water emulsions. J. Liposome Res. 2009, 19:231-240.
26. Wang T., Wang N., Song H., Xi X., Wang J., Hao A., Li T. Preparation of an anhydrous reverse micelle delivery system to enhance oral bioavailability and anti-diabetic efficacy of berberine. Eur. J. Pharm. Sci. 2011, 44:127-135.
27. Wang N., Wang T., Zhang M., Chen R., Deng Y. Using procedure of emulsification-lyophilization to form lipid A-incorporating cochleates as an effective oral mucosal vaccine adjuvant-delivery system (VADS). Int. J. Pharm. 2014, 468:39-49.
28. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
29. Frey A., Meckelein B., Externest D., Schmidt M.A. A stable and highly sensitive 3,3',5,5'-tetramethylbenzidine-based substrate reagent for enzyme-linked immunosorbent assays. J. Immunol. Methods 2000, 233:47-56.
30. Woodle M.C., Lasic D.D. Sterically stabilized liposomes. Biochim. Biophys. Acta 1992, 1113:171-199.
31. Lee B.Y., Cakouros B.E., Assi T.M., Connor D.L., Welling J., Kone S., Djibo A., Wateska A.R., Pierre L., Brown S.T. The impact of making vaccines thermostable in Niger's vaccine supply chain. Vaccine 2012, 30:5637-5643.
32. Nochi T., Takagi H., Yuki Y., Yang L., Masumura T., Mejima M., Nakanishi U., Matsumura A., Uozumi A., Hiroi T., Morita S., Tanaka K., Takaiwa F., Kiyono H. Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:10986-10991.
33. Wang S.H., Kirwan S.M., Abraham S.N., Staats H.F., Hickey A.J. Stable dry powder formulation for nasal delivery of anthrax vaccine. J. Pharm. Sci. 2012, 101:31-47.
34. Giannola L.I., Sutera F.M., De Caro V. Physical methods to promote drug delivery on mucosal tissues of the oral cavity. Expert Opin. Drug Deliv. 2013, 10:1449-1462.
35. + T cell responses induced by a recombinant live malaria vaccine in mice. PLoS ONE 2013, 6:e22442.
36. Baudner B.C., O'Hagan D.T. Bioadhesive delivery systems for mucosal vaccine delivery. J. Drug Target. 2010, 18:752-770.
37. Ensign L.M., Tang B.C., Wang Y.Y., Tse T.A., Hoen T., Cone R., Hanes J. Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci. Transl. Med. 2012, 4. 138ra179.
38. Kim S.H., Lee K.Y., Jang Y.S. Mucosal immune system and M cell-targeting strategies for oral mucosal vaccination. Immune Netw. 2012, 12:165-175.
39. Fishman M.A., Perelson A.S. Th1/Th2 differentiation and cross-regulation. Bull. Math. Biol. 1999, 61:403-436.
40. Hilleman M.R. Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. Vaccine 2003, 21:4626-4649.
41. Michel M.L., Deng Q., Mancini-Bourgine M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J. Hepatol. 2011, 54:1286-1296.